MX2021014680A - Derivado de benzotriazol. - Google Patents

Derivado de benzotriazol.

Info

Publication number
MX2021014680A
MX2021014680A MX2021014680A MX2021014680A MX2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A MX 2021014680 A MX2021014680 A MX 2021014680A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
provides
present
benzotriazole derivative
compound
Prior art date
Application number
MX2021014680A
Other languages
English (en)
Spanish (es)
Inventor
Sayaka OGI
Kazuhiro Onuma
Tomio Kimura
Akishi Ninomiya
Hiroyoshi Kawada
Naoya Kinoshita
Ken- Ichi Komori
Hayato Nishiyama
Yukinori Wada
Kousuke Morishita
Yuusuke Shiraishi
Original Assignee
Ube Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Corp filed Critical Ube Corp
Publication of MX2021014680A publication Critical patent/MX2021014680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2021014680A 2019-05-31 2020-05-29 Derivado de benzotriazol. MX2021014680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019102529 2019-05-31
PCT/JP2020/021426 WO2020241853A1 (ja) 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体

Publications (1)

Publication Number Publication Date
MX2021014680A true MX2021014680A (es) 2022-04-06

Family

ID=73553193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014680A MX2021014680A (es) 2019-05-31 2020-05-29 Derivado de benzotriazol.

Country Status (11)

Country Link
US (1) US12559504B2 (cg-RX-API-DMAC7.html)
EP (1) EP3978073B1 (cg-RX-API-DMAC7.html)
JP (1) JP7524899B2 (cg-RX-API-DMAC7.html)
KR (1) KR102978107B1 (cg-RX-API-DMAC7.html)
CN (1) CN114174289B (cg-RX-API-DMAC7.html)
AU (1) AU2020283361B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023927A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142295A1 (cg-RX-API-DMAC7.html)
ES (1) ES3047102T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021014680A (cg-RX-API-DMAC7.html)
WO (1) WO2020241853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN113024399B (zh) * 2021-03-11 2022-09-09 华东理工大学 药物中间体化合物及其制备方法、应用
KR102994906B1 (ko) * 2022-01-14 2026-07-24 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조 방법
CA3256688A1 (en) * 2022-04-28 2025-04-22 Daiichi Sankyo Company, Limited BENZOTRIAZOLE COMPOUND
WO2023210740A1 (ja) * 2022-04-28 2023-11-02 第一三共株式会社 ベンゾチオフェン化合物
EP4696692A1 (en) * 2023-06-19 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
WO2025192605A1 (ja) * 2024-03-12 2025-09-18 株式会社GALTS Pharma 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
LT3307739T (lt) * 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
KR20190088404A (ko) 2016-12-06 2019-07-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 3-(2,3-디히드로-1h-인덴-5-일)프로판산 유도체 및 nrf2 조절제로서의 그의 용도
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019116231A1 (en) * 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
US11643407B2 (en) 2018-05-23 2023-05-09 Glaxosmithkline Intellectual Property Development Limited Indanes as NRF2 activators
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
UA127872C2 (uk) 2018-12-05 2024-01-31 Скохія Фарма, Інк. Макроциклічна сполука та її застосування
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
WO2021002473A1 (ja) 2019-07-03 2021-01-07 千寿製薬株式会社 Nrf2活性化化合物
AU2021226994A1 (en) 2020-02-28 2022-09-08 Les Laboratoires Servier New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU2020283361B2 (en) 2025-11-27
CN114174289A (zh) 2022-03-11
US20220259223A1 (en) 2022-08-18
US12559504B2 (en) 2026-02-24
CA3142295A1 (en) 2020-12-03
WO2020241853A1 (ja) 2020-12-03
ES3047102T3 (en) 2025-12-03
EP3978073A4 (en) 2023-07-12
BR112021023927A2 (pt) 2022-02-08
CN114174289B (zh) 2025-03-07
KR20220016124A (ko) 2022-02-08
EP3978073B1 (en) 2025-10-15
JP7524899B2 (ja) 2024-07-30
KR102978107B1 (ko) 2026-06-16
EP3978073A1 (en) 2022-04-06
JPWO2020241853A1 (cg-RX-API-DMAC7.html) 2020-12-03
EP3978073C0 (en) 2025-10-15
AU2020283361A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
CR20160538A (es) Combinación
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
BR112021023927A2 (pt) Composto, e, composição farmacêutica
MX2018006800A (es) Composicion farmaceutica.
MX385269B (es) Compuesto de sulfonamida o sal del mismo.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2017004359A (es) Composiciones farmaceuticas que comprenden alpelisib.
BR112018074985A2 (pt) composições antibacterianas
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer